feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Sheinelle Jones TODAY co-host

trending

North Forsyth High stabbing

trending

PlayStation 2025 Wrap-Up details

trending

Medline targets $55B valuation

trending

Champions League returns on NOW

trending

Oprah features Rubirosa restaurant

trending

NBA Cup Quarterfinals begin

trending

Cher releases Christmas song

trending

California farm issues egg recall

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Earlier Cancer Doses Linked to Longer Survival

Earlier Cancer Doses Linked to Longer Survival

9 Dec

•

Summary

  • IV immunotherapy given before 3 p.m. linked to better outcomes.
  • Patients had 52% lower risk of progression, 63% lower risk of death.
  • Circadian rhythms likely influence treatment effectiveness.

A recent study indicates that the timing of cancer treatment could significantly impact patient survival. For individuals with advanced small cell lung cancer receiving IV immunotherapy, doses administered earlier in the day, specifically before 3 p.m., were associated with markedly improved outcomes.

Researchers tracked nearly 400 patients and found that those treated before 3 p.m. experienced a substantial decrease in cancer progression and mortality. This simple adjustment in infusion schedules holds promise as an inexpensive method to enhance survival rates across various healthcare settings.

The observed effects are thought to be related to the body's natural circadian rhythms, which influence bodily processes, including immune responses. While these findings are promising for immediate clinical application, further research is needed to fully understand and leverage biological rhythms for optimizing cancer therapies.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Yes, a recent study found that receiving IV immunotherapy before 3 p.m. was associated with longer survival for lung cancer patients.
Researchers suggest that the body's internal clock (circadian rhythm) may influence immune reactions, potentially enhancing the effectiveness of immunotherapy when administered at optimal times.
Adjusting the timing of IV immunotherapy infusions to earlier in the day may be a simple, cost-effective method to potentially extend survival for cancer patients.

Read more news on

Healthside-arrow

You may also like

Young Woman's Cancer Battle After Doctors Missed Signs

10 mins ago

article image

Persistent Cough? It Could Be Lung Cancer

7 Dec • 13 reads

article image

Air Pollution: A Silent Killer of Lungs

1 Dec • 45 reads

Young Adults Face Cancer Spread Risk

28 Nov • 68 reads

article image

Dual Cancer Fight: Lung Tumor Found Alongside Breast Cancer

28 Nov • 72 reads

article image